posdinemab
Johnson & Johnson Halts Phase 2 Alzheimer’s Trial After Tau Antibody Failure
Johnson & Johnson; Alzheimer’s disease; tau-targeting antibody; posdinemab; Phase 2b AuTonomy trial; clinical failure; trial discontinued
Actionable Insights Powered by AI
Johnson & Johnson; Alzheimer’s disease; tau-targeting antibody; posdinemab; Phase 2b AuTonomy trial; clinical failure; trial discontinued